Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Vedanta Biosciences announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in patients with select types of advanced or metastatic cancer.